Novel and Effective Gene Therapy for Critical Limb Ischemia

Critical limb Ischemia (CLI) represents a significant unmet medical need since there are currently no effective pharmaceuticals or biologic therapies for treatment of patients with occluded vessels. Researchers at the University of California, Davis have designed a Mesenchymal Stem/Stromal Cell (MSC) which secretes supraphysiological amounts of human Vascular Endothelial Growth Factor (VEGF) for revascularization of blood vessels and the treatment of peripheral artery diseases such as CLI. Raj Gururajan rgururajan@ucdavis.edu 530-754-7637